Biological profile of secondary hyperparathyroidism in chronic renal failure patients
Department of Biochemistry and Toxicology, Avicenna Military Hospital, Medical School Faculty, Cadi Ayyad University, Marrakech, Morocco.
Research Article
GSC Biological and Pharmaceutical Sciences, 2024, 27(02), 035–042.
Article DOI: 10.30574/gscbps.2024.27.2.0165
Publication history:
Received on 23 March 2024; revised on 03 May 2024; accepted on 06 May 2024
Abstract:
Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease, especially in hemodialysis patients. It is characterized by overproduction of parathyroid hormone in response to chronic deterioration of renal function. The aim of this retrospective study was to determine the average time to develop secondary hyperparathyroidism, analyze the initial phosphocalcic profiles, and evaluate the evolution of these profiles in hemodialysis patients, following the recommendations of the KDOQI 2003 and KDIGO 2009 groups.
The study included 134 hemodialysis patients from two private dialysis centers. Data were collected from patients' medical records and analyzed using SPSS software. The results showed that the average time to develop secondary hyperparathyroidism was 3.15 years according to KDOQI recommendations and 4.64 years according to KDIGO recommendations based on parathyroid hormone levels.
The initial assessment revealed an imbalance in phosphocalcic metabolism in approximately 20.1% to 22.5% of patients, a proportion that increased to 27.5% during follow-up, according to both sets of recommendations.
In conclusion, secondary hyperparathyroidism is an inevitable complication of chronic kidney disease, affecting the vital and functional prognosis of hemodialysis patients. Diagnosis primarily relies on parathyroid hormone levels, associated with phosphocalcemia, vitamin D, and PAL analyses. Treatment aims mainly to maintain blood levels of calcium, phosphorus, and vitamin D within recommended limits and to reduce parathyroid response to phosphocalcic disturbances.
Keywords:
Secondary hyperparathyroidism; Chronic renal failure; Hemodialysis Phosphocalcic; KDOQI and KDIGO guidelines
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
